Get a quote

We're excited to learn more about your project and provide you with a customized quote tailored to your needs. Please fill out the form below, and we'll get back to you as soon as possible.

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Liposome-mediated Gene Delivery in Precision Animal Breeding

Inquiry Now

BioVenic specializes in conducting research and laboratory-level R&D for the design of lipid nanoparticles. Through our versatile and scalable modular platform, we rapidly screen and optimize lipid particle formulations. Simultaneously, BioVenic focuses on optimizing payloads, targets, and delivery pathways to ensure the safe and reliable delivery of payloads to target tissues and efficient genome editing.

Introduction of Liposome-mediated Gene Delivery

Lipid-based delivery systems are considered to be very promising non-virus-mediated delivery methods for genome editing applications in precision animal breeding. Lipid nanoparticles (LNPs), which can be synthesized from a variety of lipid molecules, are superior gene delivery vehicles to traditional liposomes. The liposome-mediated gene delivery process uses LNPs as carriers to deliver payloads, such as CRISPR editing machinery, to target tissues and cells in vivo. This process not only protects the payload from degradation but also enhances its stability.

Schematic Diagram of Liposome-mediated Gene Delivery ProcessFig.1 Schematic Diagram of Liposome-mediated Gene Delivery Process.1

Services for Liposome-mediated Gene Delivery

Delivery Formulations Development and Synthesis

BioVenic is dedicated to designing, synthesizing, and optimizing lipid nanoparticle (LNP) formulations for our customers' nucleic acid payloads. Select various lipid components based on the specific solution to synthesize micro-vesicles for the protection of delicate genes. Our expert team customizes lipid gene delivery vectors for you, taking into account the lipid type, delivery vehicle manufacturing process, and the need for long-term stability and effectiveness.

LNP Packaging of Payload

Based on optimizing and transforming traditional lipid-based carriers, BioVenic develops and applies LNPs with significant advantages. These LNPs improve the encapsulation and transfection efficiency of gene loads and have lower cytotoxicity while penetrating target cells.

Delivery Solution Design and Optimization

We offer customers with one-stop lipid-mediated gene delivery solution customization services. Our team of liposome experts has been fully engaged in formulating and optimizing the performance of LNP. Our liposome-mediated gene delivery services undergo strict quality control system testing before delivery, such as purity, size, encapsulation rate, etc.

Flow Chart of Liposome-mediated Gene Delivery Service. (Company Original)

Why Choose Us?

Safe and effective liposomes that increase the chances of experimental success.

Safe and effective liposomes that increase the chances of experimental success.

High-quality, scalable, customized liposome-mediated delivery solutions.

High-quality, scalable, customized liposome-mediated delivery solutions.

LNPs highly suitable for in vivo gene delivery in farmed animals.

LNPs highly suitable for in vivo gene delivery in farmed animals.

Highly customized service supported by our technical experts throughout.

Highly customized service supported by our technical experts throughout.

A one-stop solution including lipid design, optimization and manufacturing, allowing you to focus on payload development.

A one-stop solution including lipid design, optimization and manufacturing, allowing you to focus on payload development.

BioVenic is committed to developing tailor-made liposome-mediated gene delivery solutions for your scientific research projects. Our expert team has extensive experience and expertise in lipid development, protocol design, and package production. We are dedicated to meeting your specific needs for LNPs in scientific research projects focused on precision breeding. If you are seeking for liposome-mediated gene delivery solution, please contact us for more details about our services.

Reference

  1. Taha, Eman A., Joseph Lee, and Akitsu Hotta. "Delivery of CRISPR-Cas tools for in vivo genome editing therapy: Trends and challenges." Journal of Controlled Release 342 (2022): 345-361.
Inquiry Basket